Skip to main content

Table 3 Detection of ACL and anti-β2GPI autoantibody-positive sera during infliximab treatment

From: Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study

  Number of positive sera Anti-β2GPI autoantibodiesa aCL autoantibodiesb
   IgG IgM IgG IgM
Infliximab, RA (n = 24) n 0 0 0 0 0
  n t 2 1c 0 5
Infliximab, AS (n = 15) n 0 0 0 0 0
  n t 0 2 3 1
Control, RA (n = 30) n 0 0 0 0 0
  n t 0 0 0 0
  1. Anti-β2GPI, anti-β2-glycoprotein I autoantibodies; aCL, anticardiolipin autoantibodies; n0, number of positive sera before treatment; nt, number of positive sera before treatment plus number of induced autoantibodies during infliximab treatment.
  2. aAnti-β2GPI with one high titer (5.4 AU/ml [IgG], 5 AU/ml [IgM]) and one moderate titer (2.1 AU/ml [IgG]), in 2 of 15 AS with two high titers (8.7 AU/ml [IgG], 3.4 AU/ml [IgM]).
  3. bLow, moderate and high titers were observed in two patients (15.1, 23 G phospholipid), in six patients (22.4, 22.8, 15.4, 21, 22.1 M phospholipid, 27 G phospholipid), and in one patient (41.5 M phospholipid) respectively.
  4. cBoth IgG and IgM.